957881-03-7

Basic information

• Product Name: AZD1152
• Synonyms: 3-[[7-[3-[Ethyl[2-(phosphonooxy)ethyl]amino]propoxy]-4-quinazolinyl]amino]-N-(3-fluorophenyl)-1H-pyrazole-5-acetamide;AZD1152 (Barasertib);2-(ETHYL(3-((4-((5-(2-((3-FLUOROPHENYL)AMINO)-2-OXOETHYL)-1H-PYRAZOL-3-YL)AMINO)QUINAZOLIN-7-YL)OXY)PROPYL)AMINO)ETHYL DIHYDROGEN PHOSPHATE
• CAS NO: 957881-03-7
• Molecular Formula: C₂₆H₃₁FN₇O₆P
• Molecular Weight: 586.5318642
• EINECS: -0
• Product Categories: Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 957881-03-7.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Density: 1.463
• CAS DataBase Reference: AZD1152(CAS DataBase Reference)
• NIST Chemistry Reference: AZD1152(957881-03-7)
• EPA Substance Registry System: AZD1152(957881-03-7)

Safety Data

• Hazardous Substances Data: 957881-03-7(Hazardous Substances Data)

Usage

Uses

As an Aurora kinase inhibitor, AZD1152 can be used to treat patients with advanced solid tumors.

Upstream product

• 446-32-2 4-fluoroanthranilic acid 
• 372-19-0 meta-fluoroaniline 
• 16499-57-3 7-fluoro-3H-quinazolin-4-one 
• 557770-91-9 2-(3-((7-(3-chloropropoxy)quinazolin-4-yl)amino)-1H-pyrazol-5-yl)acetic acid 
• 557770-90-8 4-chloro-7-(3-chloropropoxy)quinazoline 
• 557770-89-5 4-(3-phenylpropylamino)-7-(2-chloroethoxy)quinazoline 
• 722544-50-5 di-tert-butyl 2-[[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]quinazolin-7-yl}oxy)propyl](ethyl)amino]ethyl phosphate 
• 722544-51-6 N-(3-fluorophenyl)-2-{3-[(7-{3-[ethyl(2-hydroxyethyl)amino]propoxy}quinazolin-4-yl)amino]-1H-pyrazol-5-yl}acetamide 
• 174891-10-2 (5-amino-2H-pyrazol-3-yl)acetic acid 
• 722544-46-9 2-(5-{[7-(3-chloropropoxy)quinazolin-4-yl]amino}-2H-pyrazol-3-yl)-N-(3-fluorophenyl)acetamide 

Relevant articles and documents

PROCESS AND INTERMEDIATE

The invention relates to a new process useful in the preparation of pharmaceutical compounds such as 2-{ethyl[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]quinazolin-7-yl}oxy)propyl]amino}ethyl dihydrogen phosphate (AZD1152) and intermediates used therein.

COMBINATION THERAPY FOR THE TREATMENT OF CANCER

A combination comprising an aurora kinase inhibitor and an efflux transporter inhibitor wherein the aurora kinase inhibitor is a compound of formula (I) or pharmaceutically acceptable salt thereof for use in the treatment of hyperproliferative diseases such as cancer.